2041071-54-7
2041071-54-7
Chemical Structure
GNF7156
- CAS No.: 2041071-54-7
- Formula:C22H22N6O3
- Molecular Weight:418.45
InChIKey: HZCOFZVJMJRKIB-UHFFFAOYSA-N
SMILES: O=C(C1CCN(CC1)C2=C(NC(C3=C(N)N=CC(C4=CC=CC=C4)=N3)=O)C=NC=C2)O
Biological Activity: GNF7156 is a DYRK1A/GSK3B inhibitor, IC50 values of 100 nM for DYRK1A and 40 nM for GSK3B. GNF7156 inhibits DYRK1A and GSK3B kinase activity and induces NFAT nuclear retention. GNF7156 stimulates beta-cell cycle entry and division and maintains insulin secretory capacity. GNF7156 can be used for the research of type 1 diabetes, and type 2 diabetes[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
GNF7156 | GNF7156 is a DYRK1A/GSK3B inhibitor, IC50 values of 100 nM for DYRK1A and 40 nM for GSK3B. GNF7156 inhibits DYRK1A and GSK3B kinase activity and induces NFAT nuclear retention. GNF7156 stimulates beta-cell cycle entry and division and maintains insulin secretory capacity. GNF7156 can be used for the research of type 1 diabetes, and type 2 diabetes. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Shen W, et al. Inhibition of DYRK1A and GSK3B induces human β-cell proliferation. Nat Commun. 2015 Oct 26;6:8372. [Content Brief]
- [2]. Liu YA, et al. Selective DYRK1A Inhibitor for the Treatment of Type 1 Diabetes: Discovery of 6-Azaindole Derivative GNF2133. J Med Chem. 2020;63(6):2958-2973. [Content Brief]
- [3]. Shirakawa J, et al. Novel factors modulating human β-cell proliferation. Diabetes Obes Metab. 2016;18 Suppl 1(Suppl 1):71-77. [Content Brief]
